Expedeon AG: Expedeon AG information on EUR 120 million deal with Abcam on dedicated transaction website (news with additional features)

DGAP-News: Expedeon AG / Key word(s): Miscellaneous
20.11.2019 / 07:30
The issuer is solely responsible for the content of this announcement.

PRESS RELEASE
20 November 2019
 

Expedeon AG information on EUR 120 million deal with Abcam on dedicated transaction website

Heidelberg, Germany and Cambridge, UK, 20 November 2019 - Expedeon AG (Frankfurt: EXNN; ISIN: DE000A2YN801; Prime Standard) announced today that it has made information available on a dedicated website relating to the transaction agreement with Abcam plc (London Stock Exchange: ABC; ISIN: GB00B6774699; AIM MTF), Cambridge, UK.

On November 11, 2019 Expedeon announced the sale of its proteomics and immunology business activities for a cash payment of EUR 120 million. The agreement is subject to shareholder approval at an extraordinary general meeting to be held in Heidelberg on December 19th, 2019. The website also provides the relevant shareholder information.

The website is accessible at http://transaction.expedeon.com. Visitors will be asked to register.

For further information, please contact:

Expedeon AG
Dr. Heikki Lanckriet
CEO
Phone: +44 1223 873 364
Email: heikki.lanckriet@expedeon.com
Investor website: www.investors.expedeon.com

MC Services AG (Investor Relations and International Media Relations)
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 0
Email: expedeon@mc-services.eu

About Expedeon AG: www.investors.expedeon.com
Expedeon is an enabler of exciting advances in medical science and patient care. The Company's core technologies, innovative products and services are used in research laboratories around the world, enabling scientists to push the boundaries of research and product development, and play an integral part in new diagnostic tools being brought to market. With applications spanning the entire workflows in genomics, proteomics and immunology, Expedeon's technologies both accelerate and simplify research and make new and cost-effective processes available to biopharmaceutical and diagnostic organisations alike, thereby underpinning its customers' development and commercialisation objectives. Expedeon's products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. Expedeon AG has offices in Germany, Spain, UK, USA and Singapore. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: EXNN; ISIN: DE000A2YN801).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of Expedeon AG may deviate greatly from the established conclusions or implied predictions contained in such statements. Expedeon does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###

20.11.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de